Disease modification in chronic spontaneous urticaria

Area of Science:

• Immunology
• Dermatology
• Pharmacology

Background:

• Chronic spontaneous urticaria (CSU) is an inflammatory skin condition with limited treatment options focusing on symptom management.
• Current therapies do not address the underlying disease progression or pathophysiology.
• There is a critical need for treatments targeting upstream pathways to modify CSU disease course.

Purpose of the Study:

• To define "disease modification" in the context of CSU treatment interventions.
• To establish criteria for disease-modifying treatments (DMTs) in CSU.
• To identify potential therapeutic targets for CSU beyond symptom relief.

Main Methods:

• Conceptual framework development for disease modification in CSU.
• Definition of criteria for DMTs, including prevention of progression, long-term remission, and mechanism-based action.
• Review of potential therapeutic targets and biomarkers for CSU.

Main Results:

• Disease modification in CSU is defined as a favorable, enduring change in pathophysiology and disease course.
• DMT criteria include delaying progression, inducing therapy-free remission, and affecting underlying mechanisms.
• Potential DMTs may target Bruton's Tyrosine Kinase, IL-4/IL-13, IgE autoantibodies, cytokine profiles, gut microbiome, and barrier function.

Conclusions:

• Disease-modifying treatments offer a new paradigm for CSU management, moving beyond symptomatic relief.
• Future therapies should aim to halt disease progression and achieve sustained remission by targeting immune pathways.
• Developing DMTs for CSU could prevent associated comorbidities and improve long-term patient outcomes.